{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:06:16Z","timestamp":1753891576729,"version":"3.41.2"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:00:00Z","timestamp":1598313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.00921","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T07:29:23Z","timestamp":1598340563000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacodynamic Properties of Subcutaneous Immunoglobulin in Myasthenia Gravis: Sub-analyses From an Open-Label Trial"],"prefix":"10.3389","volume":"11","author":[{"given":"Brendan N.","family":"Putko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grayson","family":"Beecher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaeem A.","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1212\/CON.0000000000000800","article-title":"Myasthenia gravis and congenital myasthenic syndromes","volume":"25","author":"Ciafaloni","year":"2019","journal-title":"Continuum."},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/mus.26711","article-title":"Immunosuppressive and immunomodulatory therapies for neuromuscular diseases. Part II: new and novel agents","volume":"61","author":"Farmakidis","year":"2020","journal-title":"Muscle Nerve"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1212\/WNL.0000000000004365","article-title":"Subcutaneous immunoglobulin in myasthenia gravis exacerbation: a prospective, open-label trial","volume":"89","author":"Beecher","year":"2017","journal-title":"Neurology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1177\/1756285617722437","article-title":"Long-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin","volume":"10","author":"Kovacs","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"B5","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jocn.2019.08.113","article-title":"Efficacy and tolerability of subcutaneously administered immunoglobulin in myasthenia gravis: a systematic review","volume":"72","author":"Adiao","year":"2020","journal-title":"J Clin Neurosci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0159993","DOI":"10.1371\/journal.pone.0159993","article-title":"Subcutaneous immunoglobulin therapy in the chronic management of myasthenia gravis: a retrospective cohort study","volume":"11","author":"Bourque","year":"2016","journal-title":"PLoS ONE"},{"key":"B7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3988\/jcn.2018.14.1.98","article-title":"Subcutaneous immunoglobulins are a valuable treatment option in myasthenia gravis","volume":"14","author":"Garnero","year":"2018","journal-title":"J Clin Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1002\/mus.26353","article-title":"Subcutaneous Immunoglobulin in MG: a North American Open Label Study in 2018 AANEM Annual Meeting Abstract Guide","volume":"58","author":"Dimachkie","year":"2018","journal-title":"Muscle Nerve"},{"key":"B9","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann NY Acad Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG Composite: a valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1212\/01.wnl.0000327669.75695.38","article-title":"Treatment of ocular symptoms in myasthenia gravis","volume":"71","author":"Bhanushali","year":"2008","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/ene.13867","article-title":"Sensitivity of MG-ADL for generalized weakness in myasthenia gravis","volume":"26","author":"De Meel","year":"2019","journal-title":"Eur J Neurol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/CND.0000000000000156","article-title":"Outcome measures in myasthenia gravis: incorporation into clinical practice","volume":"18","author":"Muppidi","year":"2017","journal-title":"J Clin Neuromuscul Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/s1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1212\/WNL.0000000000004676","article-title":"Myasthenia gravis impairment index: responsiveness, meaningful change, and relative efficiency","volume":"89","author":"Barnett","year":"2017","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"CD002277","DOI":"10.1002\/14651858.CD002277.pub4","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"Gajdos","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/s1474-4422(17)30378-2","article-title":"\u2018Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Van Schaik","year":"2018","journal-title":"Lancet Neurol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/mus.25409","article-title":"Subcutaneous vs. intravenous immunoglobulin for chronic autoimmune neuropathies: a meta-analysis","volume":"55","author":"Racosta","year":"2017","journal-title":"Muscle Nerve"},{"key":"B20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/CND.0000000000000105","article-title":"Safety and efficacy of subcutaneous immunoglobulin in the treatment of neuromuscular disorders","volume":"17","author":"Salameh","year":"2016","journal-title":"J Clin Neuromuscul Dis"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00921\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T07:29:25Z","timestamp":1598340565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00921\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,25]]},"references-count":20,"alternative-id":["10.3389\/fneur.2020.00921"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.00921","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2020,8,25]]},"article-number":"921"}}